In the rapidly ageing society in Poland, osteoporosis is a growing epidemiological problem, and osteoporosis-related fractures are a cause of chronic disability and considerable increase of death risk. It turns out that 80 to 90% of patients suffering from osteoporosis, including osteoporosis accompanied by fractures, do not receive adequate pharmacotherapy. In this paper, a Guideline Working Group of experts from the Multidisciplinary Osteoporosis Forum update the existing Polish guidelines concerning the diagnosis and management of osteoporosis (last revised in 2013), taking account of the latest literature, availability and reimbursement of drugs, and current health care organisation. In the revised guidelines, we still postulate that tasks are divided between primary care doctors (stage I) and specialists in osteoporosis management (stage II). We emphasise the necessity of early initiation of pharmacotherapy and rehabilitation in all patients with low-energy fractures. We recommend that the 10-year fracture risk should be estimated in all patients (including those without fractures) who are over 50 years of age, and that the Polish threshold for therapeutic intervention should be adopted: ≥ 10% for FRAX PL calculator. We add strategies of drug choice and therapy monitoring with imaging, and densitometric and biochemical diagnostics. We define basic guidelines concerning prevention of falls, rehabilitation, and dietary procedures, and elimination of environmental and other fracture risk factors. We point to two vital elements for improving osteoporosis management: 1) strategy of supervision over fractures management -Fracture Liaison Service (FLS), and, optimally, 2) strategies of short-term monitoring of the therapeutic efficacy with the use of biochemical markers. (Endokrynol Pol 2017; 68 (5): 604-609)
Introduction
More than 2 million people within the Polish population at the age of over 50 years (every third woman and every fifth man) suffer from osteoporosis, in most cases -complicated with fractures [1] . In spite of increased mortality, worse quality of life, and higher risk of subsequent fractures following the first fracture, only 10 to 20% of such patients receive pharmacological treatment. The number of patients with a high risk of the first fracture, who receive pharmacological treatment, is on a similar, unacceptably low level [2] .
The purpose of this paper is to update and complete the existing Polish guidelines [3, 4] concerning the diagnosis and management of osteoporotic patients with or without history of fractures, with the aim of
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improving the existing status of underestimating the present osteoporosis-related threats.
Methods
A group of experts (specialists in rheumatology, orthopaedics and traumatology, internal medicine, geriatrics, endocrinology, rehabilitation, nephrology, diabetology, oncology, biochemistry, and imaging techniques) from the Multidisciplinary Osteoporosis Forum performed analysis of English-language publications in MEDLINE and COCHRANE databases concerning diagnosis, prevention, and therapeutic procedures, published from 2012 to March 2017. The agreed recommendations were preceded by abundant electronic correspondence and comments in writing. The task of the group was to update the "Guidelines" published in 2013 [3, 4] . The guidelines were rated by experts who voted using a 1-10 (10 = strongest) point scale to assess the "strength" of each recommendation in the Polish conditions. The existing guidelines were referred for review and accepted by national consultants in endocrinology, orthopaedics and traumatology, geriatrics, rheumatology, internal medicine, medical rehabilitation, diabetology, family medicine, and public health.
Management strategy
The general strategy is based on comprehensive diagnostic and therapeutic management, including division of tasks between primary care doctors at stage I and specialists treating osteoporosis at stage II.
First stage
All patients with suspected osteoporosis should be subject to selective screening including physical examination and history-taking, taking account of measure [4] .
Major fracture locations include: proximal femur (hip), vertebrae, proximal humerus, pelvis, distal radial bone [2, 4, 5] .
It should be stressed that each previous lowenergy fracture in the hip region and in other major locations highly increases the risk of subsequent fractures and is an absolute indication for fast initiation of comprehensive treatment (orthopaedic, pharmacological, analgesic, rehabilitation, and dietary interventions) [6] .
Second stage
Specialist stage, includes differential diagnostics (secondary osteoporosis, other bone diseases, comorbidities) and detailed assessment of all fracture risks, including sarcopenia, for their possible elimination and for patient education. The specialist's task is to choose an effective pharmacotherapy based on densitometry (dual-energy X-ray absorptiometry -DXA) measurements, serum Vitamin D [25(OH)D] levels, together with calcium balance assessment and, possibly, bone turnover markers.
A fundamental role in choosing medication is played by in-label indications as well as contraindications, reimbursement options, and patient preferences [7] . It is also important to decide on adjuvant treatment, rehabilitation, fall prevention, calcium and vitamin D supplementation, diet modification, and a programme of therapy monitoring ( Fig. 1 ).
In the case of a patient without low-energy fractures, pharmacotherapy is initiated by a specialist if a ≥ 10% fracture risk in major locations is confirmed in the 10-year perspective (calculated by FRAX BMD) and/or T-score upon DXA is ≤ -2.5 SD regarding hip or lumbar spine.
In the case of low-energy fractures, orthopaedic treatment should be accompanied by pharmacological treatment, followed by rehabilitation. It is always recommended that DXA and detailed diagnostic procedures are performed in order to exclude or confirm secondary osteoporosis.
In the course of treatment, it is recommended that the efficacy and safety of therapy is regularly monitored [8, 9] , and that the already existing and possibly occurring new fracture risk factors are periodically verified. Control of the patient's adherence to therapy, assessment of therapy efficacy, decision on a drug holiday, or drug switching depend on applied medication [8, 10] , periodic densitometric examination, optimally, assessment of bone markers and X-ray examination, e.g. when the patient's height decreases significantly. In secondary osteoporoses, applied procedures should be subject to the requirements of the underlying disease management [9] .
In patients with a lower fracture risk (fracture risk assessed by FRAX PL ≤ 5%), it is recommended that dietary and lifestyle prevention measures are initiated [4, 5, 7] .
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Guidelines
1.
We postulate that low-energy hip fractures in women over 50 years of age and men over 65 years of age, as well as every previous low-energy fracture in other major locations (after excluding other causes), with already existing osteopaenia (DXA, T-score < -1.5), is an obvious basis for diagnosing osteoporosis, and an indication for early initiation of comprehensive treatment (orthopaedic, pharmacological, analgesic, rehabilitation, and dietary) ["strength" 8.8].
2.
We recommend, that immediately after surgical or conservative treatment of a low-energy fracture, the orthopaedic surgeon (traumatologist) initiates either oral or parenteral pharmacotherapy, or refers the patient to a competent osteoporosis therapy centre, in order to reduce the risk of subsequent fractures [9.1].
3.
In patients of both sexes over 50 years of age, a high fracture risk in 10-year perspective (FRAX BMD ≥ 10%) or T-score ≤ -2.5 for hip or vertebrae L1-L4 is also the basis for diagnosing osteoporosis, and for initiation of treatment 
7.
Densitometry (DXA) remains the "gold standard" in osteoporosis diagnosis. The World Health Organisation (WHO) defines the following densitometric criteria for diagnosing osteoporosis on the basis of BMD measurement by means of DXA of the femoral neck (or spine) in postmenopausal women (T-score is expressed as the number of standard deviations from the reference point, which is the peak bone mineral density).
• 1) T score > −1 SD -normal value,
• 2) T score from −1 to -2.5 SD -osteopaenia, if the BMD value decreases after 12 months of the therapy in comparison to the baseline and the decrease is greater than the least significant change as measured in the same location [8.4] . 14. Denosumab is an antibody inhibiting the maturation and function of osteoclasts, and it can be used as a first-line drug or when other therapies have been unsuccessful in osteoporotic patients of both sexes. It can be administered in sequential therapy after an anabolic; it can be also given to patients with severe renal failure. Its anti-resorptive effect is reversible, and the fracture risk may increase when the drug is discontinued; therefore, drug holidays are not recommended, and where it is necessary to stop the therapy, the patient should be prescribed any other anti-resorptive drug [8.5] . 15. Despite of their established anti-fracture effect, also in severe secondary osteoporoses, parathyroid hormone (PTH) derivatives, e.g. teriparatide (anabolic drugs), are rarely used because of their high cost. When the drug is discontinued (duration of therapy is limited to 24 months), treatment should be continued with the use of another anti-resorptive drug (bisphosphonate, denosumab) as a sequential therapy. Administration of PTH derivatives immediately after anti-resorptive drugs is not recommended [8.9] . 16. Although it reduces the fracture risk, hormone replacement therapy (HRT -oestrogen-progestagen) in postmenopausal women is currently not recommended for the treatment of osteoporosis. Similarly, drugs from the SERM class (e.g. raloxifene), which reduce the risk of vertebral fractures, are used to a limited extent due to their adverse effects [8.2] .
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17. Strontium ranelate is a dual-action drug, with an established anti-fracture effect in all locations. It is efficient in patients of both sexes with osteopaenia, osteoporosis, and in the oldest patients (> 80 years of age). Due to possible thromboembolic complications and increased risk of cardiovascular diseases, the European Medicines Agency (EMA) imposed limits in its use [8.4] . 18. An important role in the prevention and treatment of osteoporosis is played by optimal (diet and/ /or supplements) intake of calcium (about 1200 mg/day), protein (1.2 g/kg of body weight /day), potassium (about 3500 mg/day), and magnesium (> 300 mg/day). The necessary component of osteoporosis prevention and treatment is an adequate Vitamin D supply (minimum 800 IU/day), while the efficacy of pharmacotherapy depends on optimal serum levels of 25(OH)D, and compensation of the calcium-phosphate balance [9] . 19. In the case of secondary osteoporoses, it is vital to effectively manage the underlying disease.
Considering the complexity of individual diseases, we recommend individualised management, possibly with reduction or elimination of osteoporosis-causing drugs, supplementation of nutrition deficiencies, kinesiotherapy, and elimination of additional fracture risk factors [8.8] . 20. An especially common iatrogenic secondary osteoporosis is glucocorticoid-induced osteoporosis (GIO) caused by chronic administration of glucocorticoids. We recommend that fracture risk should be determined and followed by preventive actions or therapy in all patients receiving prednisone (or equivalent) in a daily dose > 2. 5 
